Filterlex

Filterlex Medical is a medical technology company developing embolic protection for catheter-based structural heart procedures, particularly transcatheter aortic valve implantation (TAVI), also referred to as TAVR. The company’s goal is to help reduce the risk of stroke and other complications that can occur when particles released during these procedures travel through the bloodstream to the brain or other organs.

Its lead product, CAPTIS, is a next-generation, full-body embolic protection device designed to be positioned in the aorta during TAVI. Its triple-action approach deflects, captures and removes embolic particles, while also protecting the aortic surface. Filterlex describes CAPTIS as designed for intuitive deployment and retrieval, stable anchoring, and integration with the procedure without requiring additional access or interfering with other devices and workflow. The design is intended to accommodate anatomical variations.

Filterlex has reported successful first-in-human study results, with device performance presented at EuroPCR 2022. The company’s work is supported by clinical, engineering and regulatory expertise, and its CAPTIS program has received European Union Horizon 2020 funding.